Published in Hepatitis Weekly, June 2nd, 2003
"The safety and immunogenicity of inactivated hepatitis A (HepA) vaccine was assessed in 133 hepatitis A virus-seronegative, human immunodeficiency virus (HIV)-infected adults," scientists in the United States report.
"Patients were randomly assigned to receive, in a blinded fashion, either two doses of vaccine (1,440 enzyme-linked immunosorbent assay units) or placebo six months apart," said Carol A. Kemper and collaborators at Stanford University, the University of California-San Diego, University of Pennsylvania, and GlaxoSmithKline Biologicals....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.